Regenity Biosciences gains 510(k) clearance for RejuvaKnee™, a regenerative meniscus implant
Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, announced that it has received FDA 510(k) clearance to market RejuvaKnee™, a minimally invasive collagen-based meniscal implant indicated for use in the reinforcement and repair of soft tissue injuries of the meniscus.